MX2019013982A - Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence. - Google Patents
Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence.Info
- Publication number
- MX2019013982A MX2019013982A MX2019013982A MX2019013982A MX2019013982A MX 2019013982 A MX2019013982 A MX 2019013982A MX 2019013982 A MX2019013982 A MX 2019013982A MX 2019013982 A MX2019013982 A MX 2019013982A MX 2019013982 A MX2019013982 A MX 2019013982A
- Authority
- MX
- Mexico
- Prior art keywords
- fgf21
- growth factor
- fibroblast growth
- expression construct
- coding sequence
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 4
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 4
- 230000003612 virological effect Effects 0.000 title abstract 2
- 108091026890 Coding region Proteins 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/25—Animals on a special diet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a viral expression construct and related viral vector and nucleic acid molecule and composition and to their use wherein said construct and vector are suitable for expression in a mammal and comprise a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) to be expressed in liver, adipose tissue and/or skeletal muscle.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17172818 | 2017-05-24 | ||
ES201700615 | 2017-05-24 | ||
PCT/EP2018/063707 WO2018215613A1 (en) | 2017-05-24 | 2018-05-24 | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019013982A true MX2019013982A (en) | 2020-07-22 |
Family
ID=62620819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019013982A MX2019013982A (en) | 2017-05-24 | 2018-05-24 | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200102361A1 (en) |
EP (1) | EP3630160A1 (en) |
JP (2) | JP2020530977A (en) |
CN (1) | CN110913886A (en) |
AU (1) | AU2018274655A1 (en) |
BR (1) | BR112019024608A2 (en) |
MX (1) | MX2019013982A (en) |
RU (1) | RU2019142845A (en) |
WO (1) | WO2018215613A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3137622A1 (en) * | 2019-07-10 | 2021-01-14 | Masonic Medical Research Institute | Vgll4 with ucp-1 cis-regulatory element and method of use thereof |
IL298532A (en) * | 2020-05-26 | 2023-01-01 | Univ Barcelona Autonoma | Fibroblast growth factor 21 (fgf21) gene therapy for central nervous system disorders |
CN113956344A (en) * | 2021-10-14 | 2022-01-21 | 江南大学 | Novel FGF analogue for treating liver cancer and application thereof |
CN114010666B (en) * | 2021-10-22 | 2024-05-07 | 上海交通大学 | Application of oncolytic virus, PARP inhibitor and PD-1 antibody in preparation of antitumor drugs |
CN114316018A (en) * | 2021-11-26 | 2022-04-12 | 江南大学 | FGF21 protein analogue and application thereof |
CN117247973B (en) * | 2022-04-19 | 2024-05-10 | 康霖生物科技(杭州)有限公司 | Nucleic acid construct for treating hereditary coagulation factor deficiency disease and application thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
US6133027A (en) | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
CA2287478C (en) | 1997-04-14 | 2007-06-19 | Richard J. Samulski | Methods for increasing the efficiency of recombinant aav product |
US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
NZ500740A (en) | 1997-05-13 | 2001-02-23 | Univ North Carolina | Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV) |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
DE19909769A1 (en) | 1999-03-05 | 2000-09-07 | Bundesrepublik Deutschland Let | SIVagm-derived lentiviral vectors, processes for their preparation and their use for gene transfer in mammalian cells |
ES2327609T3 (en) | 2000-06-01 | 2009-11-02 | University Of North Carolina At Chapel Hill | PROCEDURES AND COMPOUNDS TO CONTROL THE RELEASE OF RECONBINANT PARVOVIRUS VECTORS. |
WO2002024234A2 (en) * | 2000-09-20 | 2002-03-28 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US20070015238A1 (en) | 2002-06-05 | 2007-01-18 | Snyder Richard O | Production of pseudotyped recombinant AAV virions |
CN105601748B (en) * | 2011-07-01 | 2021-08-27 | 恩格姆生物制药公司 | Compositions, uses and methods for the treatment of metabolic disorders and diseases |
MX2014002260A (en) * | 2011-08-31 | 2014-08-18 | Amgen Inc | Fgf21 for use in treating type 1 diabetes. |
EP2692868A1 (en) * | 2012-08-02 | 2014-02-05 | Universitat Autònoma De Barcelona | Adeno-associated viral (AAV) vectors useful for transducing adipose tissue |
US9290557B2 (en) * | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
WO2014085365A2 (en) * | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
CN105916990B (en) * | 2013-08-02 | 2020-02-04 | 巴塞罗那自治大学 | Adeno-associated virus vector for transduction of adipose tissue |
CA3120923A1 (en) * | 2018-11-26 | 2020-06-04 | Universitat Autonoma De Barcelona | Fibroblast growth factor 21 (fgf21) gene therapy |
-
2018
- 2018-05-24 JP JP2019565341A patent/JP2020530977A/en active Pending
- 2018-05-24 MX MX2019013982A patent/MX2019013982A/en unknown
- 2018-05-24 CN CN201880047871.5A patent/CN110913886A/en active Pending
- 2018-05-24 EP EP18731359.8A patent/EP3630160A1/en active Pending
- 2018-05-24 US US16/615,854 patent/US20200102361A1/en not_active Abandoned
- 2018-05-24 BR BR112019024608-8A patent/BR112019024608A2/en unknown
- 2018-05-24 WO PCT/EP2018/063707 patent/WO2018215613A1/en unknown
- 2018-05-24 RU RU2019142845A patent/RU2019142845A/en unknown
- 2018-05-24 AU AU2018274655A patent/AU2018274655A1/en active Pending
-
2023
- 2023-05-30 JP JP2023089121A patent/JP2023109992A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110913886A (en) | 2020-03-24 |
AU2018274655A1 (en) | 2019-12-19 |
EP3630160A1 (en) | 2020-04-08 |
WO2018215613A1 (en) | 2018-11-29 |
RU2019142845A3 (en) | 2021-09-20 |
US20200102361A1 (en) | 2020-04-02 |
JP2023109992A (en) | 2023-08-08 |
JP2020530977A (en) | 2020-11-05 |
RU2019142845A (en) | 2021-06-24 |
BR112019024608A2 (en) | 2020-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019013982A (en) | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence. | |
SA517390590B1 (en) | Modified Factor IX, and Compositions, Methods and Uses for Gene Transfer to Cells, Organs and Tissues | |
MX2017004488A (en) | Pharmaceutical compositions comprising peptide variants and methods of use thereof. | |
MX2020004578A (en) | Casz compositions and methods of use. | |
MX2016003944A (en) | Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof. | |
MX2018000470A (en) | Antibody molecules which bind cd22. | |
WO2015183890A3 (en) | Methods and compositions for the treatment of metabolic disorders and diseases | |
MX2018000147A (en) | Antibody molecules which bind cd45. | |
BR112017003406A2 (en) | chromobacterium subtsugae genome | |
MX2022001971A (en) | Modified interleukin 2 (il-2) polypeptides, conjugates and uses thereof. | |
NZ628625A (en) | Polypeptides binding to human complement c5 | |
MX2017009767A (en) | Novel proteins specific for angiogenesis. | |
ES2531290T3 (en) | Transferases and oxidoreductases, nucleic acids that encode them and methods to prepare and use them | |
EA201692359A1 (en) | COMPOSITION BASED ON NEW PRRSV STRAIN OR HIS PROTEINS, PRODUCT, THEIR USE, PRRSV VIRUS, ISOLATED NK AND A RECOMBINANT VECTOR OF EXPRESSION FOR OBTAINING THIS VIRUS | |
WO2018118997A3 (en) | Polymerizing enzymes for sequencing reactions | |
SG10201810321PA (en) | α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | |
MX2023000804A (en) | Peptides for use in promoting transport of glucose. | |
AR110093A1 (en) | D-PSYCHOSE 3-EPIMERASE AND METHOD TO PREPARE D-PSYCHOSE USING THE SAME | |
PH12019501193A1 (en) | Use of chelating agents for improving color stability of resorcinol | |
IN2015DN03206A (en) | ||
MX2017015786A (en) | Compositions and methods for treating celiac sprue disease. | |
WO2015185758A3 (en) | Preparation comprising factor viii and von willebrand factor peptides | |
MX2020000414A (en) | Neoantigen vaccine composition for treatment of cancer. | |
NZ734705A (en) | Herbicide resistance protein, and encoding genes and application thereof | |
WO2016036635A8 (en) | Chromobacterium subtsugae genes |